Treating Prolactinomas with Dopamine Agonists: Always Worth the Gamble?

Overview

Journal Endocrine

Specialty Endocrinology

Date 2015 Sep 5

PMID 26336835

Citations 19

Authors

Sean Noronha

Victoria Stokes

Niki Karavitaki

Ashley Grossman

Affiliations

Soon will be listed here.

Abstract

Dopamine agonists are the treatment of choice for all patients with prolactinomas. They are generally safe, effective, and well-tolerated. However, a link between their use and the development of impulse control disorders has been well recognized in the field of neurology for some time, and evidence for a similar effect in endocrine patients is emerging. This has mainly been revealed through clinical case reports, plus a small number of comparative studies of varying robustness. We review the current available literature and discuss the implications for clinical practice, in particular emphasizing the need for clinicians to be alert to these uncommon but serious adverse effects.

Citing Articles

A Narrative Review of Surgery for Prolactinomas: Considerations and Controversies.

Mann J, Starreveld Y, Riva-Cambrin J, Lithgow K J Clin Med. 2025; 14(4).

PMID: 40004619 PMC: 11856391. DOI: 10.3390/jcm14041089.

Prolactinoma: Navigating the Dual Challenge of Side Effects and Treatment Strategies - A Comprehensive Review.

Yogeeta F, Rauf S, Devi M, Imran K, Ahmed R, Aruwani P Ann Med Surg (Lond). 2024; 86(8):4613-4623.

PMID: 39118737 PMC: 11305738. DOI: 10.1097/MS9.0000000000002308.

Clinical use of [F]fluoro-ethyl-L-tyrosine PET co-registered with MRI for localizing prolactinoma remnants.

van Trigt V, Bakker L, Lu H, Pelsma I, Verstegen M, van Furth W Pituitary. 2024; 27(5):614-624.

PMID: 39042164 PMC: 11513721. DOI: 10.1007/s11102-024-01430-y.

Care trajectories of surgically treated patients with a prolactinoma: why did they opt for surgery?.

van Trigt V, Zandbergen I, Pelsma I, Bakker L, Verstegen M, van Furth W Pituitary. 2023; 26(5):611-621.

PMID: 37690076 PMC: 10539430. DOI: 10.1007/s11102-023-01346-z.

Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report.

Correa E Castro A, de Araujo A, Botelho M, Nascimento J, de Souza R, Gadelha M Front Psychiatry. 2022; 13:844718.

PMID: 35693961 PMC: 9178067. DOI: 10.3389/fpsyt.2022.844718.

References

Auriemma R, Pivonello R, Ferreri L, Priscitelli P, Colao A . Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am. 2015; 44(1):89-97. DOI: 10.1016/j.ecl.2014.10.007. View

Weiss H, Marsh L . Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease. Neurol Clin Pract. 2013; 2(4):267-274. PMC: 3613210. DOI: 10.1212/CPJ.0b013e318278be9b. View

Delgado V, Biermasz N, van Thiel S, Ewe S, Ajmone Marsan N, Holman E . Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol (Oxf). 2012; 77(1):99-105. DOI: 10.1111/j.1365-2265.2011.04326.x. View

Barake M, Evins A, Stoeckel L, Pachas G, Nachtigall L, Miller K . Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2013; 17(2):150-6. PMC: 4109390. DOI: 10.1007/s11102-013-0480-6. View

Auriemma R, Pivonello R, Perone Y, Grasso L, Ferreri L, Simeoli C . Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur J Endocrinol. 2013; 169(3):359-66. DOI: 10.1530/EJE-13-0231. View

Seeman P . Parkinson's disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015; 69(4):183-9. DOI: 10.1002/syn.21805. View

Elenkova A, Shabani R, Kalinov K, Zacharieva S . Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment. Eur J Endocrinol. 2012; 167(1):17-25. DOI: 10.1530/EJE-12-0121. View

Cornelius J, Tippmann-Peikert M, Slocumb N, Frerichs C, Silber M . Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010; 33(1):81-7. PMC: 2802252. View

Bancos I, Nannenga M, Bostwick J, Silber M, Erickson D, Nippoldt T . Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf). 2013; 80(6):863-8. PMC: 4136510. DOI: 10.1111/cen.12375. View

10.

Thondam S, Alusi S, ODriscoll K, Gilkes C, Cuthbertson D, Daousi C . Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma. Clin Neuropharmacol. 2013; 36(5):170-2. DOI: 10.1097/WNF.0b013e31829fc165. View

11.

Ahlskog J . Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol Behav. 2011; 104(1):168-72. DOI: 10.1016/j.physbeh.2011.04.055. View

12.

Viana M, Andrade L . Lifetime Prevalence, age and gender distribution and age-of-onset of psychiatric disorders in the São Paulo Metropolitan Area, Brazil: results from the São Paulo Megacity Mental Health Survey. Braz J Psychiatry. 2013; 34(3):249-60. DOI: 10.1016/j.rbp.2012.03.001. View

13.

Moraes A, Dos Santos Silva C, Vieira Neto L, Gadelha M . Giant prolactinomas: the therapeutic approach. Clin Endocrinol (Oxf). 2013; 79(4):447-56. DOI: 10.1111/cen.12242. View

14.

Premaratne V, Saeger I, MacDonald B . Lesson of the month (1): cabergoline - 'i eat funny on that'. Clin Med (Lond). 2014; 14(2):205-7. PMC: 4953297. DOI: 10.7861/clinmedicine.14-2-205. View

15.

Casanueva F, Molitch M, Schlechte J, Abs R, Bonert V, Bronstein M . Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf). 2006; 65(2):265-73. DOI: 10.1111/j.1365-2265.2006.02562.x. View

16.

Gu H, Luck S, Carroll P, Powrie J, Chambers J . Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias?. Clin Endocrinol (Oxf). 2011; 74(5):608-10. DOI: 10.1111/j.1365-2265.2010.03973.x. View

17.

Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P . Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011; 34(5):179-81. DOI: 10.1097/WNF.0b013e3182281b2f. View

18.

Falhammar H, Yarker J . Pathological gambling and hypersexuality in cabergoline-treated prolactinoma. Med J Aust. 2009; 190(2):97. DOI: 10.5694/j.1326-5377.2009.tb02289.x. View

19.

Maiter D, Primeau V . 2012 update in the treatment of prolactinomas. Ann Endocrinol (Paris). 2012; 73(2):90-8. DOI: 10.1016/j.ando.2012.03.024. View

20.

Davie M . Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci. 2007; 19(4):473-4. DOI: 10.1176/jnp.2007.19.4.473. View